ID   PER-494
AC   CVCL_A8JU
DR   Wikidata; Q108821103
RX   PubMed=33937032;
CC   Miscellaneous: Sampling site from personal communication of Kotecha, Rishi S.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=33937032
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8,12
ST   D16S539: 11
ST   D21S11: 30.2,31.2
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 6,9
ST   TPOX: 9
ST   vWA: 15,16
DI   NCIt; C122617; Infant acute lymphoblastic leukemia with MLL rearrangement
DI   ORDO; Orphanet_513; Acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_W984 ! PER-485
SX   Female
AG   11M
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 10-09-24; Version: 5
//
RX   PubMed=33937032; DOI=10.3389/fonc.2021.631594; PMCID=PMC8082024;
RA   Cheung, Laurence C.
RA   de Kraa, Rebecca
RA   Oommen, Joyce
RA   Chua, Grace-Alyssa
RA   Singh, Sajla
RA   Hughes, Anastasia M.
RA   Ferrari, Emanuela
RA   Ford, Jette
RA   Chiu, Sung K.
RA   Stam, Ronald W.
RA   Kees, Ursula R.
RA   Malinge, Sebastien
RA   Kotecha, Rishi S.
RT   "Preclinical evaluation of carfilzomib for infant KMT2A-rearranged
RT   acute lymphoblastic leukemia.";
RL   Front. Oncol. 11:631594.1-631594.13(2021).
//